It was important to note that combination of CDK2 inhibitor (K03861) and paclitaxel, the first-line chemotherapeutic drug of TNBC, resulted in synergistic tumor growth inhibition of TNBC cells. This evidence concerns the gene CDK2 and neoplasm.